CCS
RMD icon

Crosspoint Capital Strategies’s ResMed RMD Stock Holding History

Crosspoint Capital Strategies’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,800
Closed -$101K – 662
2015
Q4 		$101K Buy
+1,800
New +$101K 0.03% 328

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Crosspoint Capital Strategies's RMD Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of ResMed (RMD) in Q1 2016, closing a stake of 1,800 shares — an estimated $101K sold.

Crosspoint Capital Strategies first reported a position in RMD in Q4 2015 and held it in 1 quarter. The position peaked at $101K in Q4 2015. 374 funds tracked by Wall St. Rank hold RMD as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining ResMed position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 1,800 ResMed shares in Q1 2016, an estimated $101K.
  • Crosspoint Capital Strategies first reported a position in ResMed in Q4 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's ResMed position peaked at $101K in Q4 2015.
  • 374 funds tracked by Wall St. Rank held ResMed as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.